Ocular

Ocular Therapeutix is a biopharmaceutical company developing and commercializing therapies for serious retinal diseases. It leverages a proprietary hydrogel technology for sustained-release drug delivery, aiming to reduce treatment frequency. Their pipeline includes AXPAXLI™ (OTX-TKI), an investigational axitinib hydrogel in Phase 3 trials for wet age-related macular degeneration, designed for a less burdensome regimen.

Amarpreet S. Sawhney and Farhad Khosravi founded Ocular Therapeutix on September 12, 2006. Dr. Sawhney, a chemical engineer and serial entrepreneur, recognized the burden of chronic eye disease treatments. The company was established with the insight that prolonged drug delivery could improve patient adherence and outcomes by minimizing frequent invasive procedures.

Ocular Therapeutix serves patients with chronic retinal conditions like wet AMD, diabetic retinopathy, and retinal vein occlusion. It strives to transform the patient experience by providing therapies reducing frequent injections and clinic visits. Their vision is to advance ophthalmic care, preserving vision and enhancing quality of life through innovative, less burdensome solutions.